EUVIMEDEUVIMED entdecken
Crossref

Therapeutic Effects of Albumin-Fused BMP7 on 2 Experimental Models of Liver Fibrosis

Mei Takano, Hiroshi Watanabe, Shota Toda, Kento Nishida, Tadashi Imafuku, Yuki Minayoshi, Takehiro Nakano, Hitoshi Maeda, Toru Maruyama

Biological and Pharmaceutical Bulletin · 2023

DOI: 10.1248/bpb.b23-00254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Mei Takano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University. Hauptthemen laut MEDLINE: Liver Cirrhosis, Bone Morphogenetic Protein 7. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the fact that liver fibrosis is an intractable disease with a poor prognosis, effective therapeutic agents are not available. In this study, we focused on bone morphogenetic factor 7 (BMP7) that inhibits transforming growth factor (TGF)-β signaling, which is involved in liver fibrosis. We prepared an albumin-fused BMP7 (HSA-BMP7) that is retained in the blood and evaluated its inhibitory effect on liver fibrosis. Bile duct ligated mice were used as an acute liver fibrosis model, and carbon tetrachloride-induced liver fibrosis mice were used as a chronic model. All mice were administered HSA-BMP7 once per week. In the mice with bile duct ligation, the administration of HSA-BMP7 significantly suppressed the infiltration of inflammatory cells, the area of fibrosis around the bile duct, and decreased in the level of hydroxyproline as compared with saline administration. The mRNA expression of TGF-β and its downstream fibrosis-associated genes (α-SMA and Col1a2) were also suppressed by the administration of HSA-BMP7. In the carbon tetrachloride-induced liver fibrosis mice, the HSA-BMP7 administration significantly decreased the hepatic fibrosis area and the level of hydroxyproline. Based on these results, it appears that HSA-BMP7 has the potential for serving as a therapeutic agent for the treatment of liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisBone Morphogenetic Protein 7AnimalsMiceAlbuminsCarbon TetrachlorideHydroxyprolineLiverTransforming Growth Factor beta1Collagen Type I

Stichwörter der Autor:innen

albumin fusionborn morphogenetic protein-7liver fibrosistransforming growth factor-β

Substanzen

AlbuminsCarbon TetrachlorideHydroxyprolineTransforming Growth Factor beta1Bone Morphogenetic Protein 7Collagen Type I, alpha2 SubunitCollagen Type I

Autor:innen und Institutionen

  • Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University.

Zitieren

APA

Takano, M., Watanabe, H., Toda, S., Nishida, K., Imafuku, T., Minayoshi, Y., Nakano, T., Maeda, H., & Maruyama, T. (2023). Therapeutic Effects of Albumin-Fused BMP7 on 2 Experimental Models of Liver Fibrosis. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b23-00254

Vancouver

Takano M, Watanabe H, Toda S, Nishida K, Imafuku T, Minayoshi Y, et al. Therapeutic Effects of Albumin-Fused BMP7 on 2 Experimental Models of Liver Fibrosis. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b23-00254

BibTeX
@article{Takano2023,
  author = {Takano, Mei and Watanabe, Hiroshi and Toda, Shota and Nishida, Kento and Imafuku, Tadashi and Minayoshi, Yuki and Nakano, Takehiro and Maeda, Hitoshi and Maruyama, Toru},
  title = {Therapeutic Effects of Albumin-Fused BMP7 on 2 Experimental Models of Liver Fibrosis},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2023},
  doi = {10.1248/bpb.b23-00254}
}
Kostenlos starten →